295 related articles for article (PubMed ID: 33144077)
1. Considerations for setting occupational exposure limits for novel pharmaceutical modalities.
Graham JC; Hillegass J; Schulze G
Regul Toxicol Pharmacol; 2020 Dec; 118():104813. PubMed ID: 33144077
[TBL] [Abstract][Full Text] [Related]
2. Special endpoint and product specific considerations in pharmaceutical acceptable daily exposure derivation.
Gould J; Callis CM; Dolan DG; Stanard B; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S79-93. PubMed ID: 27233924
[TBL] [Abstract][Full Text] [Related]
3. The regulatory framework for preventing cross-contamination of pharmaceutical products: History and considerations for the future.
Sargent EV; Flueckiger A; Barle EL; Luo W; Molnar LR; Sandhu R; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S3-S10. PubMed ID: 27230736
[TBL] [Abstract][Full Text] [Related]
4. Strategies for preventing occupational exposure to potent compounds.
Calhoun DM; Coler AB; Nieusma JL
Toxicol Mech Methods; 2011 Feb; 21(2):93-6. PubMed ID: 20507226
[TBL] [Abstract][Full Text] [Related]
5. Challenges of Using Closed System Transfer Devices With Biological Drug Products: An Industry Perspective.
Sreedhara A; Zamiri C; Goswami S; Weiser S; Cram M; Christian TR; Jagannathan B
J Pharm Sci; 2020 Jan; 109(1):22-29. PubMed ID: 31697946
[TBL] [Abstract][Full Text] [Related]
6. Setting Occupational Exposure Limits for Genotoxic Substances in the Pharmaceutical Industry.
Lovsin Barle E; Winkler GC; Glowienke S; Elhajouji A; Nunic J; Martus HJ
Toxicol Sci; 2016 May; 151(1):2-9. PubMed ID: 27207978
[TBL] [Abstract][Full Text] [Related]
7. Setting occupational exposure limits for unstudied pharmaceutical intermediates using an in vitro parallelogram approach.
Maier MS
Toxicol Mech Methods; 2011 Feb; 21(2):76-85. PubMed ID: 20156007
[TBL] [Abstract][Full Text] [Related]
8. A harmonization effort for acceptable daily exposure application to pharmaceutical manufacturing - Operational considerations.
Hayes EP; Jolly RA; Faria EC; Barle EL; Bercu JP; Molnar LR; Naumann BD; Olson MJ; Pecquet AM; Sandhu R; Shipp BK; Sussman RG; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S39-47. PubMed ID: 27267172
[TBL] [Abstract][Full Text] [Related]
9. Occupational toxicology and the control of exposure to pharmaceutical agents at work.
Binks SP
Occup Med (Lond); 2003 Sep; 53(6):363-70. PubMed ID: 14514902
[TBL] [Abstract][Full Text] [Related]
10. Using default methodologies to derive an acceptable daily exposure (ADE).
Faria EC; Bercu JP; Dolan DG; Morinello EJ; Pecquet AM; Seaman C; Sehner C; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S28-38. PubMed ID: 27233926
[TBL] [Abstract][Full Text] [Related]
11. Occupational Exposure Risks When Working with Protein Therapeutics and the Development of a Biologics Banding System.
Graham J; Yao H; Franklin E
Appl Biosaf; 2021 Dec; 26(4):193-204. PubMed ID: 36034098
[No Abstract] [Full Text] [Related]
12. Australian consensus guidelines for the safe handling of monoclonal antibodies for cancer treatment by healthcare personnel.
Alexander M; King J; Bajel A; Doecke C; Fox P; Lingaratnam S; Mellor JD; Nicholson L; Roos I; Saunders T; Wilkes J; Zielinski R; Byrne J; MacMillan K; Mollo A; Kirsa S; Green M
Intern Med J; 2014 Oct; 44(10):1018-26. PubMed ID: 25302720
[TBL] [Abstract][Full Text] [Related]
13. Guidance on the establishment of acceptable daily exposure limits (ADE) to support Risk-Based Manufacture of Pharmaceutical Products.
Sargent EV; Faria E; Pfister T; Sussman RG
Regul Toxicol Pharmacol; 2013 Mar; 65(2):242-50. PubMed ID: 23291300
[TBL] [Abstract][Full Text] [Related]
14. [Recent prevention strategies and occupational risk analysis: Control Banding and Sobane].
Ghittori S; Ferrari M; Negri S; Serranti P; Sacco P; Biffi R; Imbriani M
G Ital Med Lav Ergon; 2006; 28(1):30-43. PubMed ID: 16705887
[TBL] [Abstract][Full Text] [Related]
15. A harmonization effort for acceptable daily exposure derivation - Considerations for application of adjustment factors.
Sussman RG; Naumann BD; Pfister T; Sehner C; Seaman C; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S57-66. PubMed ID: 27221789
[TBL] [Abstract][Full Text] [Related]
16. Point of departure (PoD) selection for the derivation of acceptable daily exposures (ADEs) for active pharmaceutical ingredients (APIs).
Bercu JP; Morinello EJ; Sehner C; Shipp BK; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S48-56. PubMed ID: 27233925
[TBL] [Abstract][Full Text] [Related]
17. Harmonization efforts for deriving health-based exposure limits in the pharmaceutical industry - Advancing the current science and practice.
Weideman PA; Pecquet AM; Maier MA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S1-2. PubMed ID: 27531049
[No Abstract] [Full Text] [Related]
18. Issues and approaches for ensuring effective communication on acceptable daily exposure (ADE) values applied to pharmaceutical cleaning.
Olson MJ; Faria EC; Hayes EP; Jolly RA; Barle EL; Molnar LR; Naumann BD; Pecquet AM; Shipp BK; Sussman RG; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S19-27. PubMed ID: 27233923
[TBL] [Abstract][Full Text] [Related]
19. Safe handling of hazardous drugs.
Polovich M
Online J Issues Nurs; 2004 Sep; 9(3):6. PubMed ID: 15482092
[TBL] [Abstract][Full Text] [Related]
20. Identifying and assessing highly hazardous drugs within quality risk management programs.
Sussman RG; Schatz AR; Kimmel TA; Ader A; Naumann BD; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S11-8. PubMed ID: 27267171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
